Mary Clare McGregor, MD
Pulmonary Disease · Saint Louis, MONPI 1467899328
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 3 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by United Therapeutics Corporation at 37.2% of the total. That places this record below the midpoint for pulmonary disease clinicians in MO, where the typical reported total is $1,482.
Across 3 payments — averaging $112.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$125
- La Jolla Pharmaceutical Company$112
- Sanofi$99
Across 11 payments — averaging $34,616 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$381K
What the payments were for
- Food & beverage$336100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 1 | $125 |
| La Jolla Pharmaceutical Company | 1 | $112 |
| Sanofi | 1 | $99 |
How this compares
$336 in reported general payments places this provider in the 30th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 53 | $699,875 |
| Pirfenidone | 18 | $88,512 |
| TezspireTezepelumab-Ekko | 14 | $63,246 |
| NucalaMepolizumab | 11 | $40,577 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $30,384 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 24 | $11,275 |
| Spiriva RespimatTiotropium Bromide | 17 | $11,043 |
| SymbicortBudesonide/Formoterol Fumarate | 40 | $10,297 |
| Mycophenolate Mofetil | 82 | $6,173 |
| Wixela InhubFluticasone Propion/Salmeterol | 13 | $2,668 |
| Pulmicort FlexhalerBudesonide | 12 | $2,097 |
| Azathioprine | 20 | $1,412 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 38 | $969 |
| Prednisone | 126 | $442 |
| Azithromycin | 16 | $137 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Saint Louis
- Derek ByersSaint Louis$835K
- Alexander ChenSaint Louis$679K
- Joseph OjileSaint Louis$538K
- Edward CharbekSaint Louis$372K
- Marin KollefSaint Louis$264K
- Praveen ChennaSaint Louis$255K
- Murali ChakinalaSaint Louis$172K
- Janet LeeSaint Louis$143K
- Ali SadoughiSaint Louis$87K
- Ramsey HachemSaint Louis$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.